Arama Sonuçları - Iris Kuss

  • Gösterilen 1 - 13 sonuçlar arası kayıtlar. 13
Sonuçları Daraltın
  1. 1
    Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer

    Randomized phase II study of lonaprisan as second-line therapy for progesterone receptor-positive breast cancer Yazar: W. Jonat, Thomas Bachelot, Thomas Ruhstaller, Iris Kuss, U. Reimann, John F. R. Robertson

    Baskı/Yayın Bilgisi 2013
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  2. 2
    Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

    Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer Yazar: Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, Christian Kappeler, Amir Snapir, Toni Sarapohja, Matthew R. Smith

    Baskı/Yayın Bilgisi 2019
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  3. 3
    Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide

    Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide Yazar: Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, Marie‐Aude Le Berre, Oana Petrenciuc, Amir Snapir, Toni Sarapohja, Matthew Smith

    Baskı/Yayın Bilgisi 2020
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  4. 4
    223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate cancer (nmCRPC)

    223P Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for non-metastatic castration-resistant prostate can... Yazar: Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, M-A. Le Berre, Oana Petrenciuc, Amir Snapir, Toni Sarapohja, Matthew Smith

    Baskı/Yayın Bilgisi 2020
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  5. 5
    Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial

    Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial Yazar: Jun Pang, Neal D. Shore, Matthew R. Smith, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, Marie A. Le Berre, Amir Snapir, Toni Sarapohja, Karim Fizazi

    Baskı/Yayın Bilgisi 2019
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  6. 6
    Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

    Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Result... Yazar: Neal D. Shore, Christian Zurth, Robert E. Fricke, Hille Gieschen, Kristina Graudenz, Mikko Koskinen, Bart A. Ploeger, Jonathan Moss, Olaf Prien, Gustavo Borghesi, Oana Petrenciuc, Teuvo L.J. Tammela, Iris Kuss, Frank Verholen, Matthew R. Smith, Karim Fizazi

    Baskı/Yayın Bilgisi 2019
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  7. 7
    Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High- or Low-volume Metastatic Hormone-sensitive Prostate Cancer: Analyses of the Randomized Phase 3 ARASENS Study

    Deep and Durable Prostate-specific Antigen Response to Darolutamide with Androgen Deprivation Therapy and Docetaxel, and Association with Clinical Outcomes for Patients with High-... Yazar: Fred Saad, Maha Hussain, Bertrand Tombal, Karim Fizazi, Cora N. Sternberg, E. David Crawford, Luke T. Nordquist, Martin Bögemann, Ronald Tutrone, Neal D. Shore, Laurence Belkoff, Todd Fralich, Jay Jhaveri, Shankar Srinivasan, Rui Li, Frank Verholen, Iris Kuss, Matthew R. Smith

    Baskı/Yayın Bilgisi 2024
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  8. 8
    Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial

    Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: An analysis of the phase III ARAMIS trial Yazar: Matthew R. Smith, Neal D. Shore, Teuvo L.J. Tammela, Albertas Ulys, Egils Vjaters, S. Polyakov, Mindaugas Jievaltas, Murilo Luz, B. Yа. Alekseev, Iris Kuss, Marie-Aude Le Berre, Ateesha F. Mohamed, Dawn Odom, Jennifer Bartsch, Amir Snapir, Toni Sarapohja, Karim Fizazi

    Baskı/Yayın Bilgisi 2021
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  9. 9
    Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial

    Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial Yazar: Maha Hussain, Bertrand Tombal, Fred Saad, Karim Fizazi, Cora N. Sternberg, E. David Crawford, Neal D. Shore, Evgeny Kopyltsov, Arash Rezazadeh Kalebasty, Martin Bögemann, Dingwei Ye, Felipe José Silva Melo Cruz, Hiroyoshi Suzuki, Shivani Kapur, Shankar Srinivasan, Frank Verholen, Iris Kuss, Heikki Joensuu, Matthew R. Smith

    Baskı/Yayın Bilgisi 2023
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  10. 10
    Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study

    Effect of crossover from placebo to darolutamide on overall survival in men with non-metastatic prostate cancer: sensitivity analyses from the randomised phase 3 ARAMIS study Yazar: Neal D. Shore, Karim Fizazi, Teuvo L.J. Tammela, Murilo Luz, Manuel Philco Salas, Paul Ouellette, S. Lago, Diogo Assed Bastos, G. Kenneth Jansz, Flavio Mavignier Cárcano, Lívia Barboza de Andrade, Marc Pliskin, Nicolas Lazaretti, Larissa Arruda, José Jaime Correa Ochoa, Iris Kuss, Christian Kappeler, Toni Sarapohja, Matthew R. Smith

    Baskı/Yayın Bilgisi 2023
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  11. 11
    Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial

    Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-... Yazar: George D. Demetri, Peter Reichardt, Yoon‐Koo Kang, Jean‐Yves Blay, Piotr Rutkowski, Hans Gelderblom, Peter Hohenberger, Michael Leahy, Margaret von Mehren, Heikki Joensuu, Giuseppe Badalamenti, Martin E. Blackstein, Axel Le Cesne, Patrick Schöffski, Robert G. Maki, Sebastian Bauer, Binh Bui Nguyen, Jianming Xu, Toshirou Nishida, John Chung, Christian Kappeler, Iris Kuss, Dirk Laurent, Paolo G. Casali

    Baskı/Yayın Bilgisi 2012
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  12. 12
    Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer

    Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer Yazar: Matthew R. Smith, Maha Hussain, Fred Saad, Karim Fizazi, Cora N. Sternberg, E. David Crawford, Evgeny Kopyltsov, Chandler H. Park, B. Yа. Alekseev, Álvaro Montesa-Pino, Dingwei Ye, Francis Parnis, Felipe José Silva Melo Cruz, Teuvo L.J. Tammela, Hiroyoshi Suzuki, Tapio Utriainen, Cheng Fu, Motohide Uemura, María José Méndez-Vidal, Benjamin L. Maughan, Heikki Joensuu, Silke Thiele, Rui Li, Iris Kuss, Bertrand Tombal

    Baskı/Yayın Bilgisi 2022
    Tam Metin Erişim Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:
  13. 13
    Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS

    Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS Yazar: Neal D. Shore, Christian Gratzke, Susan Feyerabend, Patrick Werbrouck, Joan Carles, Egils Vjaters, Teuvo L.J. Tammela, David Morris, Jeanny B. Aragon‐Ching, Raoul S. Concepcion, Urban Emmenegger, Neil Fleshner, Markus Grabbert, V. Lietuvietis, Hakim Mahammedi, Francisco Cruz, Adriano Augusto Peclat de Paula, Christopher Pieczonka, Antti Rannikko, Martin Eduardo Richardet, Glauco Costa Silveira, Iris Kuss, Marie‐Aude Le Berre, Frank Verholen, Toni Sarapohja, Matthew Ryan Smith, Karim Fizazi

    Baskı/Yayın Bilgisi 2024
    Tam Metin Erişim
    Artigo
    Favorilerime ekle
    Kaydedildi:

Arama Araçları: